The results presented in this thesis show that hRSV infection in humans results in a multifaceted immune response, which cannot be described as purely Th1- or Th2-like. However, the observed higher level of IL-13 producing hRSV-specific T cells in infants hospitalized with severe hRSV bronchiolitis could provide a clue for an immunopathological mechanism of natural hRSV-mediated severe disease. Another hRSV-specific immunological factor potentially involved in the pathogenesis of severe hRSV disease could be the frequency and/or phenotype like those of HLADP4-restricted T cell responses directed to the conserved region of the RSV G protein. The BBG2Na- and rMVA-F/G-based vaccination strategies evaluated in infant macaques resulted in low VN and cellular immune responses and no detectable protection. A combination of both approaches in a prime-boost regime could possibly increase vaccine immunogenicity, but in this case the immunopathological safety would again have to be evaluated in different animal models.

, , ,
EC 5th FWP (grant no. QLK2-1999-01044), Netherlands Asthma Foundation (grant no. NAF 93.96.1), Netherlands Organisation for Health Science (grant no. 940-35-025), Osterhaus, Prof. Dr. A.D.M.E. (promotor), Sophia Foundation for Medical Research (grant no. 214)
A.D.M.E. Osterhaus (Albert)
Erasmus University Rotterdam
hdl.handle.net/1765/1170
Erasmus MC: University Medical Center Rotterdam

de Waal, L. (2003, December 10). Respiratory Syncytial Virus; Anti-viral immunity in humans and macaques.. Retrieved from http://hdl.handle.net/1765/1170

Additional Files
03.pdf Final Version , 3mb
04.pdf Final Version , 2mb
01.pdf Final Version , 1mb
02.pdf Final Version , 1mb
20.pdf Final Version , 912kb
22.pdf Final Version , 214kb
21.pdf Final Version , 129kb
003.pdf Final Version , 112kb
30.pdf Final Version , 111kb
00.pdf Final Version , 102kb
001.pdf Final Version , 99kb
004.pdf Final Version , 80kb
31.pdf Final Version , 78kb
Waal_front.jpg Cover Image , 61kb